Section Arrow
LYRA.NASDAQ
- Lyra Therapeutics Inc
(Financial Status)
Quotes are at least 15-min delayed:2026/02/23 07:21 EST
Pre Market
Last
 --
-- (--)
Bid
1.4
Ask
1.49
High -- 
Low -- 
Volume -- 
Regular Hours (Closed)
Last
 1.45
-0.04 (-2.68%)
Day High 
1.505 
Prev. Close
1.49 
1-M High
2.58 
Volume 
12.86K 
Bid
1.4
Ask
1.49
Day Low
1.45 
Open
1.49 
1-M Low
1.2129 
Market Cap 
2.64M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 1.49 
20-SMA 1.72 
50-SMA 2.65 
52-W High 37.5 
52-W Low 1.2129 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-22.90/-6.35
Enterprise Value
32.90M
Balance Sheet
Book Value Per Share
-2.44
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
1.53M
Operating Revenue Per Share
0.80
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
CDIOCardio Diagnostics Holdings Inc.2.88+0.64+28.57%-- 
Pre Market 2.82 -0.06 -2.08%
IBRXImmunityBio8.7+0.09+1.05%-- 
Pre Market 8.75 +0.05 +0.57%
GERNGeron Corp1.88-0.04-2.08%-- 
Pre Market 1.85 -0.03 -1.60%
QNCXQuince Therapeutics0.1501-0.0121-7.46%-- 
Pre Market 0.1492 -0.0009 -0.60%
RXRXRecursion Pharmaceuticals3.42-0.3-8.06%-- 
Pre Market 3.369 -0.051 -1.49%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.